Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney

被引:52
作者
Wagner, SN
Atkinson, MJ
Wagner, C
Hofler, H
Schmitt, M
Wilhelm, O
机构
[1] GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT, INST PATHOL, D-85758 OBERSCHLEISSHEIM, GERMANY
[2] TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, FRAUENKLIN, D-81675 MUNICH, GERMANY
[3] TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, INST PATHOL, D-81675 MUNICH, GERMANY
关键词
D O I
10.1007/BF01450878
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The urokinase-type plasminogen activator (uPA) is secreted into the urine at high concentrations and both the uPA protein and mRNA are present in human renal tissue. Normal kidney tissue also expresses the receptor for uPA. Neither the precise sites of uPA mRNA expression, nor the distribution of the uPA-receptor antigen, have been elucidated in the human kidney. In the present study, the sites of uPA mRNA expression were identified by in situ hybridization, and the cellular localization of both uPA and uPA-receptor was determined by immunohistochemical analysis. High-level uPA mRNA expression was restricted to epithelial cells of the convoluted proximal tubules and the thick ascending limb of Henle's loop (the straight part of the distal tubule). However, uPA immunoreactivity was not confined to sites of uPA mRNA expression, but was present in all segments of the tubular epithelium. Tubular epithelial cells also exhibited a consistent immunoreactivity with uPA-receptor antibody, indicative of a co-localization of the uPA antigen and its receptor in the uriniferous epithelium. We propose that the uPA antigen expression in nephron segments lacking demonstrable endogenous uPA synthesis may be the result of a uPA-receptor-mediated uptake of uPA.
引用
收藏
页码:53 / 60
页数:8
相关论文
共 35 条
  • [1] INHIBITION OF PROTEIN-SYNTHESIS IN LLC-PK1 CELLS INCREASES CALCITONIN-INDUCED PLASMINOGEN-ACTIVATOR GENE-TRANSCRIPTION AND MESSENGER-RNA STABILITY
    ALTUS, MS
    PEARSON, D
    HORIUCHI, A
    NAGAMINE, Y
    [J]. BIOCHEMICAL JOURNAL, 1987, 242 (02) : 387 - 392
  • [2] BAKER MS, 1990, CANCER RES, V50, P4676
  • [3] NOVEL IMMUNOHISTOCHEMICAL MARKERS OF HUMAN RENAL-ALLOGRAFT DYSFUNCTION - ANTITHROMBIN-III, THY-1, UROKINASE, AND ALPHA-SMOOTH MUSCLE ACTIN
    BUKOVSKY, A
    LABARRERE, CA
    CARTER, C
    HAAG, B
    FAULK, WP
    [J]. TRANSPLANTATION, 1992, 54 (06) : 1064 - 1071
  • [4] CHUCHOLOWSKI N, 1992, FIBRINOLYSIS, V6, P95
  • [5] PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER
    DANO, K
    ANDREASEN, PA
    GRONDAHLHANSEN, J
    KRISTENSEN, P
    NIELSEN, LS
    SKRIVER, L
    [J]. ADVANCES IN CANCER RESEARCH, 1985, 44 : 139 - 266
  • [6] 2-CHAIN UROKINASE, RECEPTOR, AND TYPE-1 INHIBITOR IN CULTURED HUMAN MESANGIAL CELLS
    GLASS, WF
    KREISBERG, JI
    TROYER, DA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (03): : F532 - F539
  • [7] SPECIES-DIFFERENCES IN THE DETECTION OF HIGH-MOLECULAR-WEIGHT URINARY PLASMINOGEN ACTIVATORS
    HART, DA
    REHEMTULLA, A
    BABINS, EM
    [J]. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1986, 84 (03): : 287 - 293
  • [8] DISTRIBUTION OF PLASMINOGEN ACTIVATORS IN HUMAN-KIDNEY AND MALE GENITAL ORGANS USING A HIGHLY SENSITIVE ENZYME-IMMUNOASSAY
    HASUI, Y
    SUZUMIYA, J
    SUMIYOSHI, A
    HASHIDA, S
    ISHIKAWA, E
    [J]. THROMBOSIS RESEARCH, 1988, 51 (04) : 453 - 459
  • [9] Hata M, 1989, Nihon Hinyokika Gakkai Zasshi, V80, P1558
  • [10] HEARING VJ, 1988, CANCER RES, V48, P1270